BR112015023725A2 - composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme - Google Patents
composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filmeInfo
- Publication number
- BR112015023725A2 BR112015023725A2 BR112015023725A BR112015023725A BR112015023725A2 BR 112015023725 A2 BR112015023725 A2 BR 112015023725A2 BR 112015023725 A BR112015023725 A BR 112015023725A BR 112015023725 A BR112015023725 A BR 112015023725A BR 112015023725 A2 BR112015023725 A2 BR 112015023725A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage composition
- film dosage
- self
- formation process
- supporting
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/842,543 US20140271788A1 (en) | 2013-03-15 | 2013-03-15 | Sublingual and buccal film compositions |
| US14/196,082 US9511033B2 (en) | 2013-03-15 | 2014-03-04 | Sublingual and buccal film compositions |
| PCT/US2014/028568 WO2014144241A1 (en) | 2013-03-15 | 2014-03-14 | Sublingual and buccal film compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015023725A2 true BR112015023725A2 (pt) | 2017-07-18 |
Family
ID=51528033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023725A BR112015023725A2 (pt) | 2013-03-15 | 2014-03-14 | composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20140271788A1 (enExample) |
| EP (1) | EP2968121B1 (enExample) |
| JP (2) | JP6448096B2 (enExample) |
| KR (1) | KR20160029730A (enExample) |
| CN (1) | CN105491997B (enExample) |
| AU (1) | AU2014227693B2 (enExample) |
| BR (1) | BR112015023725A2 (enExample) |
| CA (1) | CA2906773C (enExample) |
| DK (1) | DK2968121T3 (enExample) |
| IL (1) | IL241441B (enExample) |
| MX (1) | MX2015013184A (enExample) |
| MY (1) | MY181159A (enExample) |
| RU (1) | RU2015143647A (enExample) |
| WO (1) | WO2014144241A1 (enExample) |
| ZA (1) | ZA201507685B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271788A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| AU2015341490C1 (en) | 2014-11-07 | 2021-03-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
| US20160175296A1 (en) * | 2014-12-23 | 2016-06-23 | Arx, Llc | Method of producing uniform buprenorphine-containing formulations |
| EP3281625B1 (en) * | 2015-04-07 | 2020-02-26 | Nipro Corporation | Oral film preparation |
| KR102851614B1 (ko) | 2016-02-04 | 2025-08-29 | 신돔 파마, 인크. | 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법 |
| US11738036B2 (en) | 2016-05-28 | 2023-08-29 | Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Biotechnology, Government Of India | Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma |
| JP2020500220A (ja) | 2016-11-15 | 2020-01-09 | クラリア ファーマ ホールディング エービー | 医薬製剤 |
| CA3045043A1 (en) | 2016-12-31 | 2018-07-05 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| WO2019240212A1 (ja) * | 2018-06-14 | 2019-12-19 | 株式会社カネカ | 薬学的活性成分を含む製剤 |
| CN115154440A (zh) | 2018-06-27 | 2022-10-11 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
| US11648197B2 (en) * | 2018-06-28 | 2023-05-16 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
| GB201819978D0 (en) * | 2018-12-11 | 2019-01-23 | Univ Strathclyde | Oral thin films |
| JP7287032B2 (ja) | 2019-03-20 | 2023-06-06 | 株式会社リコー | シート、シート積層体、医薬品、シートの製造方法、及びシート積層体の製造方法 |
| WO2021016112A2 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| US11806320B2 (en) * | 2020-02-19 | 2023-11-07 | Endo Ventures Limited | Isoproterenol compositions and methods |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| WO2025147530A1 (en) * | 2024-01-05 | 2025-07-10 | Taho Pharmaceuticals Ltd. | Naloxone buccal film product and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3493657A (en) | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
| US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
| US4366159A (en) | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
| GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US5225417A (en) | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
| US5223507A (en) | 1992-01-21 | 1993-06-29 | G. D. Searle & Co. | Method of using opioid compounds as delta opioid selective agonist analgesics |
| GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| ATE214276T1 (de) | 1994-09-19 | 2002-03-15 | Du Pont Pharm Co | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit |
| US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| AT403162B (de) | 1995-10-11 | 1997-11-25 | Nycomed Austria Gmbh | Neue kristallform von morphin-6-glucuronid |
| DE19602969A1 (de) | 1995-12-20 | 1997-07-31 | Nycomed Arzneimittel Gmbh | Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung |
| PT914097E (pt) | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
| WO1998035679A1 (de) | 1997-02-14 | 1998-08-20 | Gödecke Aktiengesellschaft | Stabilisierung von naloxonhydrochlorid |
| KR100514963B1 (ko) | 1997-07-11 | 2005-09-15 | 도레이 가부시끼가이샤 | 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물 |
| ATE210983T1 (de) | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum |
| IT1302682B1 (it) | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
| US20140271788A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US20110033542A1 (en) * | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| CA2530843A1 (en) * | 2003-07-01 | 2005-01-20 | Todd Maibach | Film comprising therapeutic agents |
| DE602004017514D1 (de) | 2004-06-02 | 2008-12-11 | Galephar M F | Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon |
| US20060046962A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| WO2006026713A2 (en) * | 2004-08-31 | 2006-03-09 | Tracie Martyn International, Llc | Topical benfotiamine and pyridoxamine compositions |
| JP2007304673A (ja) | 2006-05-09 | 2007-11-22 | Kyocera Mita Corp | 監視装置及び監視システム並びに監視プログラム |
| US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
-
2013
- 2013-03-15 US US13/842,543 patent/US20140271788A1/en not_active Abandoned
-
2014
- 2014-03-04 US US14/196,082 patent/US9511033B2/en active Active
- 2014-03-14 BR BR112015023725A patent/BR112015023725A2/pt not_active Application Discontinuation
- 2014-03-14 MY MYPI2015703198A patent/MY181159A/en unknown
- 2014-03-14 JP JP2016502836A patent/JP6448096B2/ja active Active
- 2014-03-14 CA CA2906773A patent/CA2906773C/en active Active
- 2014-03-14 AU AU2014227693A patent/AU2014227693B2/en active Active
- 2014-03-14 DK DK14721650.1T patent/DK2968121T3/en active
- 2014-03-14 KR KR1020157028424A patent/KR20160029730A/ko not_active Withdrawn
- 2014-03-14 EP EP14721650.1A patent/EP2968121B1/en active Active
- 2014-03-14 CN CN201480027179.8A patent/CN105491997B/zh active Active
- 2014-03-14 MX MX2015013184A patent/MX2015013184A/es unknown
- 2014-03-14 RU RU2015143647A patent/RU2015143647A/ru not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/028568 patent/WO2014144241A1/en not_active Ceased
-
2015
- 2015-09-10 IL IL241441A patent/IL241441B/en active IP Right Grant
- 2015-10-14 ZA ZA2015/07685A patent/ZA201507685B/en unknown
-
2016
- 2016-12-05 US US15/369,101 patent/US20170296482A1/en not_active Abandoned
-
2018
- 2018-10-09 US US16/155,100 patent/US20190038570A1/en not_active Abandoned
- 2018-11-30 JP JP2018225191A patent/JP2019048882A/ja not_active Abandoned
-
2019
- 2019-12-06 US US16/705,422 patent/US20200315984A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015143647A (ru) | 2017-04-21 |
| IL241441B (en) | 2019-07-31 |
| EP2968121A1 (en) | 2016-01-20 |
| US20140271788A1 (en) | 2014-09-18 |
| JP6448096B2 (ja) | 2019-01-09 |
| CN105491997A (zh) | 2016-04-13 |
| IL241441A0 (en) | 2015-11-30 |
| WO2014144241A1 (en) | 2014-09-18 |
| KR20160029730A (ko) | 2016-03-15 |
| CA2906773C (en) | 2023-12-12 |
| US20200315984A1 (en) | 2020-10-08 |
| AU2014227693A1 (en) | 2015-10-29 |
| US9511033B2 (en) | 2016-12-06 |
| CN105491997B (zh) | 2019-12-17 |
| MY181159A (en) | 2020-12-19 |
| DK2968121T3 (en) | 2019-02-04 |
| AU2014227693B2 (en) | 2018-06-21 |
| MX2015013184A (es) | 2016-04-07 |
| ZA201507685B (en) | 2017-06-28 |
| EP2968121B1 (en) | 2018-12-19 |
| US20170296482A1 (en) | 2017-10-19 |
| US20140271789A1 (en) | 2014-09-18 |
| JP2019048882A (ja) | 2019-03-28 |
| CA2906773A1 (en) | 2014-09-18 |
| US20190038570A1 (en) | 2019-02-07 |
| JP2016513736A (ja) | 2016-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023725A2 (pt) | composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
| MX356865B (es) | Nuevas soluciones terapéuticas para tratar la enfermedad de parkinson. | |
| PH12015502302A1 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
| BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
| BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| BR112014030279A2 (pt) | métodos para tratamento de neutropenia usando agonistas retinóide | |
| MX2016008397A (es) | Composicion para usarse en el tratamiento de tos persistente. | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| FI20115165A0 (fi) | Terapeuttisia ja diagnostisia menetelmiä | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| BR112015022513A2 (pt) | produto e método para tratamento de diarreia | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| BR112018069174A2 (pt) | tratamento de prurido urêmico | |
| BR112016012248A2 (pt) | método de tratamento de nefropatia | |
| BR112016013923A2 (pt) | Modulador de cetp para o uso no tratamento de enfermidade ocular | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| BR112016014099A2 (pt) | método de tratamento de feridas | |
| BR112015026805A2 (pt) | métodos e tratamento para determinadas desordens baseadas em dismielinização e desmielinização e/ ou promoção da remielinização | |
| BR112016014617A2 (pt) | Variante do fator xa (fxa) e usos da referida variante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: AQUESTIVE THERAPEUTICS, INC. (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |